Article Text

Download PDFPDF

610 Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors
  1. Kevin Harrington1,
  2. Pablo Nenclares2,
  3. Isla Leslie1,
  4. Ari VanderWalde3,
  5. Tawnya Bowles4,
  6. Joseph Sacco5,
  7. Anna Olsson-Brown5,
  8. Jiaxin Niu6,
  9. Katy Tsai7,
  10. Jason Chesney8,
  11. Bartosz Chmielowski9,
  12. Adel Samson10,
  13. Terence Rhodes4,
  14. Gino In11,
  15. Anna Pavlick12,
  16. Trisha Wise-Draper13,
  17. Miguel Sanmamed14,
  18. Laxminarasimha Donthireddy15,
  19. Yawei Zhang15,
  20. Jeannie Hou15,
  21. Praveen Bommareddy15,
  22. Robert Coffin15,
  23. Mark Middleton16 and
  24. Mohammed Milhem17
  1. 1Royal Marsden NHS Foundation Trust & ICR, Sutton, UK
  2. 2The Institute of Cancer Research, London, UK
  3. 3West Cancer Center and Research Institute, Germantown, TN, United States
  4. 4Intermountain Medical Center, Murray, UT, United States
  5. 5Clatterbridge Cancer Centre, Liverpool, UK
  6. 6Banner MD Anderson Cancer Center, Gilbert, AZ, United States
  7. 7Helen Diller Family Comprehensive Cancer, San Francisco, CA, United States
  8. 8James Graham Brown Cancer Center, Louisville, KY, United States
  9. 9University of California Los Angeles, Los Angeles, CA, United States
  10. 10University of Leeds, Leeds, UK
  11. 11Norris Comprehensive Cancer Center, Los Angeles, CA, United States
  12. 12Weill Cornell Medical College, New York, NY, United States
  13. 13University of Cincinnati, Cincinnati, OH, United States
  14. 14Clínica Universidad de Navarra, New Haven, CT, United States
  15. 15Replimune Inc, Woburn, MA, United States
  16. 16Churchill Hospital, Oxford, UK
  17. 17Holden Comprehensive Cancer Center, Iowa City, IA, United States


Background RP1 is a novel, enhanced potency, oncolytic version of HSV-1 engineered to express human GM-CSF and GALV-GP R-.1 RP1 + anti-PD1 therapy combination has resulted in deep and durable responses, including in melanoma patients who have previously failed prior anti-PD1 therapy.2 Here we present biomarker data from the ongoing clinical trial of RP1 + nivolumab (nivo).

Methods Tumor biopsies were taken pre-treatment and at 43 days after the first dose of RP1. The tumor immune microenvironment (TIME) was analyzed IHC for CD8 (SP57 clone, Ventana) and PD-L1 (PD-L1 IHC 28-8 pharmDx by Agilent) and by gene expression analysis using the NanoString IO360 panel. The tumor inflammation signature score (TIS) was also calculated using an 18 gene signature.3 Systemic anti-tumor immunity was assessed using PBMCs by sequencing the CDR3 regions of human TCRβ chains using the immunoSEQ assay. Correlation analysis of baseline tumor PD-L1 and CD8 status versus clinical response was also performed.

Results A consistent increase in CD8 and PD-L1 expression in the tumor was observed in most of the tested biopsies (30/44), which generally appeared to be co-located. These increases were observed both in superficial lesions and visceral tumors, including in the liver. A notable reversal of CD8 T cell exclusion was observed in a melanoma patient who failed prior ipilimumab and nivo treatment. Clinical responses were independent of baseline CD8 T cell infiltration, PD-L1 expression levels, and prior anti-PD-1 therapy. Gene expression analyses of tumor biopsies (n=11) demonstrated significant increases in the expression levels of genes associated with innate and adaptive immune activation and genes previously reported to be associated with responsiveness to anti-PD1 therapy, particularly CD8, CXCL9, CD27, and TIGIT, as well as consistent increases in TIS. TCR sequencing of PBMCs revealed expansion of pre-existing T cell clones and the appearance of new clones with 20-80% of these changes being newly detected clones. Expansion of new clones (n=170) was observed in a melanoma patient who had a complete response.

Conclusions The biomarker data indicate broad immune activation by RP1 + nivo. Clinical responses are independent of baseline PD-L1 expression and associated with increases in gene signatures associated with cytotoxic T, NK, and Th1 cells. The data indicate the potential for broad utility of RP1 in a range of tumor types, including in patients with primary or acquired resistance to immune checkpoint blockade.

Trial Registration NCT03767348


  1. Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7(1):214.

  2. Milhem M, Vanderwalde V, Bowles T, Sacco J, Niu J, Tsai K, Chesney J, Chmielowski B, Samson A, Rhodes T, In G, Pavlick A, Wise-Draper T, Sanmamed M, Bommareddy P, Zhu J, Coffin R, Harrington K, and Middleton M. Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). Journal of Clinical Oncology. 2022;40(16_suppl):9553-9553

  3. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-?-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930-2940.

Ethics Approval The study was approved by the institutional review board or the local ethics committee at each participating site. Informed consent was obtained from patients before participating in the trial.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.